Document is current
Any future updates will be listed below
-
Authors
Ferreira, Sara A. http://orcid.org/0000-0001-6943-514X
Li, Conghui
Klæstrup, Ida H.
Vitic, Zagorka
Rasmussen, Rikke K. http://orcid.org/0000-0002-3366-7931
Kirkegaard, Asger
Toft, Gitte U.
Betzer, Cristine
Svendsen, Pia
Jensen, Poul H. http://orcid.org/0000-0002-4439-9020
Luo, Yonglun http://orcid.org/0000-0002-0007-7759
Etzerodt, Anders http://orcid.org/0000-0002-6757-2068
Moestrup, Søren K.
Romero-Ramos, Marina http://orcid.org/0000-0003-0970-578X
- License Information
-
More Information
Article History
Received: 29 November 2022
Accepted: 24 November 2023
First Online: 13 December 2023
Competing interests
: S.K.M. and A.E. are founders and shareholders of OncoSpears Aps which holds IP protecting the use of CD163 targeting. M.R.-R. is Associate Editor of <i>npj Parkinson’s Disease</i>. M.R.-R. was not involved in the journal’s review of, or decisions related to, this manuscript. The remaining authors declare no competing financial or non-financial interests.
